🇺🇸 FDA
Pipeline program

Pegcetacoplan

APL2-PNH-209

Phase 2 small_molecule active

Quick answer

Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 2 program (small_molecule) at Apellis Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Apellis Pharmaceuticals
Indication
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials